Literature DB >> 18334041

Argatroban therapy in patients with hepatic and renal impairment.

P-A Brand, J-H Egberts, J Scholz, N Weiler, B Bein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18334041     DOI： 10.1017/S0265021507002839

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN： 0265-0215            Impact factor:   4.330


× No keyword cloud information.
  4 in total

1.  Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.

Authors:  Duane Bates; Sarah Griffin; Barb Angel
Journal:  Can J Hosp Pharm       Date:  2009-07

2.  Argatroban dose reductions for suspected heparin-induced thrombocytopenia complicated by child-pugh class C liver disease.

Authors:  Peter M Yarbrough; Amir Varedi; Amanda Walker; Matthew T Rondina
Journal:  Ann Pharmacother       Date:  2012-10-16       Impact factor: 3.154

Review 3.  Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.

Authors:  Marcie J Hursting; Joseph Soffer
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  Functional and binding studies of gallic acid showing platelet aggregation inhibitory effect as a thrombin inhibitor.

Authors:  Yuxin Zhang; Xing Wang; Binan Lu; Yanbin Gao; Yanling Zhang; Yatong Li; Hongjuan Niu; Lu Fan; Zongran Pang; Yanjiang Qiao
Journal:  Chin Herb Med       Date:  2021-09-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.